Anterior|Próximo

Carga global da hiperplasia prostática benigna, infecções do trato urinário, urolitíase, câncer de bexiga, câncer renal e câncer de próstata de 1990 a 2021

  • role： Contribute equally, First author同等贡献者, 第一作者
  • Affiliation：

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

    Evidence-Based Medicine Center, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang 441000, Hubei, China

Hao Zi12,  
  • role： Contribute equally同等贡献者
  • Affiliation：

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

    Department of Urology, Wuhan Clinical Research Center of Tumors of the Urinary System and Male Genital Organs, Hubei Key Laboratory of Urinary System Diseases, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Meng-Yang Liu13,  
  • role： Contribute equally同等贡献者
  • Affiliation：

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Li-Sha Luo1,  
  • Affiliation：

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Qiao Huang1,  
  • Affiliation：

    Department of Urology, Wuhan Clinical Research Center of Tumors of the Urinary System and Male Genital Organs, Hubei Key Laboratory of Urinary System Diseases, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

    Department of Urology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan 430060, China

Peng-Cheng Luo34,  
  • Affiliation：

    Department of Forensic Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Hang-Hang Luan5,  
  • Affiliation：

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Jiao Huang1,  
  • Affiliation：

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

    Department of Urology, Wuhan Clinical Research Center of Tumors of the Urinary System and Male Genital Organs, Hubei Key Laboratory of Urinary System Diseases, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Dan-Qi Wang13,  
  • Affiliation：

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Yong-Bo Wang1,  
  • Affiliation：

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Yuan-Yuan Zhang1,  
  • Affiliation：

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

    Department of Urology, Wuhan Clinical Research Center of Tumors of the Urinary System and Male Genital Organs, Hubei Key Laboratory of Urinary System Diseases, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Ren-Peng Yu13,  
  • Affiliation：

    School of Clinical Medicine, Hubei University of Arts and Science, Xiangyang 441053, Hubei, China

Yi-Tong Li6,  
  • role： Corresponding author通信作者
  • Affiliation：

    Department of Urology, Wuhan Clinical Research Center of Tumors of the Urinary System and Male Genital Organs, Hubei Key Laboratory of Urinary System Diseases, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

  • Email：zh-urology@whu.edu.cn
  • Introduction：* zh-urology@whu.edu.cn
Hang Zheng3*,  
  • role： Corresponding author通信作者
  • Affiliation：

    Department of Urology, Wuhan Clinical Research Center of Tumors of the Urinary System and Male Genital Organs, Hubei Key Laboratory of Urinary System Diseases, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

  • Email：liutongzu@163.com
  • Introduction：liutongzu@163.com
Tong-Zu Liu3*,  
  • role： Corresponding author通信作者
  • Affiliation：

    Department of Urology, Institute of Urology, Peking University First Hospital, Peking University, The National Urological Cancer Center of China, Beijing 100034, China

  • Email：dantefanbmu@pku.edu.cn
  • Introduction：dantefanbmu@pku.edu.cn
Yu Fan7*,  
  • role： Corresponding author通信作者
  • Affiliation：

    Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

    Department of Urology, Wuhan Clinical Research Center of Tumors of the Urinary System and Male Genital Organs, Hubei Key Laboratory of Urinary System Diseases, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

  • Email：zengxiantao1128@whu.edu.cn
  • Introduction：zengxiantao1128@whu.edu.cn
Xian-Tao Zeng13*

Resumo

Background:The burden of common urologic diseases, including benign prostatic hyperplasia (BPH), urinary tract infections (UTI), urolithiasis, bladder cancer, kidney cancer, and prostate cancer, varies both geographically and within specific regions. It is essential to conduct a comprehensive and precise assessment of the global burden of urologic diseases.Methods:We obtained data on incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) for the aforementioned urologic diseases by age, sex, location, and year from the Global Burden of Disease (GBD) 2021. We analyzed the burden associated with urologic diseases based on socio-demographic index (SDI) and attributable risk factors. The trends in burden over time were assessed using estimated annual percentage changes (EAPC) along with a 95% confidence interval (CI).Results:In 2021, BPH and UTI were the leading causes of age-standardized incidence rate (ASIR) and age-standardized prevalence rate (ASPR), with rates of 5531.88 and 2782.59 per 100,000 persons, respectively. Prostate cancer was the leading cause of both age-standardized mortality rate (ASMR) and age-standardized DALYs rate (ASDR), with rates of 12.63 and 217.83 per 100,000 persons, respectively. From 1990 to 2021, there was an upward trend in ASIR, ASPR, ASMR, and ASDR for UTI, while urolithiasis showed a downward trend. The middle and low-middle SDI quintile levels exhibited higher incidence, prevalence, mortality, and DALYs related to UTI, urolithiasis, and BPH, while the high and high-middle SDI quintile levels showed higher rates for the three cancers. The burden of these 6 urologic diseases displayed diverse age and sex distribution patterns. In 2021, a high body mass index (BMI) contributed to 20.07% of kidney cancer deaths worldwide, while smoking accounted for 26.48% of bladder cancer deaths and 3.00% of prostate cancer deaths.Conclusions:The global burden of 6 urologic diseases presents a significant public health challenge. Urgent international collaboration is essential to advance the improvement of urologic disease management, encompassing the development of effective diagnostic screening tools and the implementation of high-quality prevention and treatment strategies.

Palavras-chave

Benign prostatic hyperplasia (BPH);Urinary tract infections (UTI);Urolithiasis;Bladder cancer;Kidney cancer;prostate cancer;Disability-adjusted life-years (DALYs);Burden of disease

References

  1. 1..
    Miller DC, Saigal CS, Litwin MS. The demographic burden of urologic diseases in America. Urol Clin North Am. 2009;36(1):11-27.
  2. 2..
    Okeke CJ, Jeje EA, Obi AO, Ojewola RW, Ogbobe UU. The burden of urologic diseases in a tertiary hospital in South-Eastern Nigeria: a three-year review. J West Afr Coll Surg. 2023;13(4):78-82.
  3. 3..
    Choi SY, Yoon CG. Urologic diseases in Korean military population: a 6-year epidemiological review of medical records. J Korean Med Sci. 2017;32(1):135-42.
  4. 4..
    Zi H, He SH, Leng XY, Xu XF, Huang Q, Weng H, et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019. Mil Med Res. 2021;8(1):60.
  5. 5..
    Zhu C, Wang DQ, Zi H, Huang Q, Gu JM, Li LY, et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res. 2021;8(1):64.
  6. 6..
    Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.
  7. 7..
    GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440): 2133-61.
  8. 8..
    GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100-32.
  9. 9..
    GBD 2021 Demographics Collaborators. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):1989-2056.
  10. 10..
    Kim YE, Jung YS, Ock M, Yoon SJ. DALY estimation approaches: understanding and using the incidence-based approach and the prevalence-based approach. J Prev Med Public Health. 2022;55(1):10-8.
  11. 11..
    GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-49.
  12. 12..
    GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22.
  13. 13..
    Liu Y, Wen H, Bai J, Sun J, Chen J, Yu C. Disease burden and prediction analysis of tracheal, bronchus, and lung cancer attributable to residential radon, solid fuels, and particulate matter pollution under different sociodemographic transitions from 1990 to 2030. Chest. 2024;165(2):446-60.
  14. 14..
    GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440): 2162-203.
  15. 15..
    Hankey BF, Ries LA, Kosary CL, Feuer EJ, Merrill RM, Clegg LX, et al. Partitioning linear trends in age-adjusted rates. Cancer Causes Control. 2000;11(1):31-5.
  16. 16..
    Huang Q, Yang J, Liu GX, Zi H, Tang SD, Jia HC, et al. Changes in disease burden and global inequalities in bladder, kidney and prostate cancers from 1990 to 2019: a comparative analysis based on the global burden of disease study 2019. BMC Public Health. 2024;24(1):891.
  17. 17..
    GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203-34.
  18. 18..
    Dai X, Gakidou E, Lopez AD. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tob Control. 2022;31(2):129-37.
  19. 19..
    GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13-27.
  20. 20..
    Khadembashiri MM, Ghasemi E, Khadembashiri MA, Azadnajafabad S, Moghaddam SS, Eslami M, et al. The global, regional, and national burden and quality of care index of kidney cancer; a global burden of disease systematic analysis 1990–2019. Int J Qual Health Care. 2024;36(1):mzad113.
  21. 21..
    Cirillo L, Innocenti S, Becherucci F. Global epidemiology of kidney cancer. Nephrol Dial Transpl. 2024;39(6):920-8.
  22. 22..
    GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2204-56.
  23. 23..
    Wise J. Global life expectancy to increase by almost five years by 2050, study predicts. BMJ. 2024;385:q1126.
  24. 24..
    Cepeda-Benito A, Doogan NJ, Redner R, Roberts ME, Kurti AN, Villanti AC, et al. Trend differences in men and women in rural and urban U.S. settings. Prev Med. 2018;117:69-75.
  25. 25..
    Lucca I, Klatte T, Fajkovic H, de Martino M, Shariat SF. Gender differences in incidence and outcomes of urothelial and kidney cancer. Nat Rev Urol. 2015;12(10):585-92.
  26. 26..
    Horstmann M, Witthuhn R, Falk M, Stenzl A. Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med. 2008;5(4):385-94.
  27. 27..
    Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M, et al. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol. 2013;31(5):1029-36.
  28. 28..
    Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, et al. Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. Eur J Surg Oncol. 2015;41(3):368-77.
  29. 29..
    Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, et al. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 2014;83(4):863-7.
  30. 30..
    Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology. 2004;64(2):383-8.
  31. 31..
    Sottnik JL, Vanderlinden L, Joshi M, Chauca-Diaz A, Owens C, Hansel DE, et al. Androgen receptor regulates CD44 expression in bladder cancer. Cancer Res. 2021;81(11):2833-46.
  32. 32..
    Shortliffe LM, Ye Y, Behr B, Wang B. Testosterone changes bladder and kidney structure in juvenile male rats. J Urol. 2014;191(6):1913-9.
  33. 33..
    Pischon T, Lahmann PH, Boeing H, Tjønneland A, Halkjaer J, Overvad K, et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006;118(3):728-38.
  34. 34..
    Callahan CL, Hofmann JN, Corley DA, Zhao WK, Shuch B, Chow WH, et al. Obesity and renal cell carcinoma risk by histologic subtype: a nested case-control study and meta-analysis. Cancer Epidemiol. 2018;56:31-7.
  35. 35..
    MacLeod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, et al. Risk factors for renal cell carcinoma in the VITAL study. J Urol. 2013;190(5):1657-61.
  36. 36..
    Keimling M, Behrens G, Schmid D, Jochem C, Leitzmann MF. The association between physical activity and bladder cancer: systematic review and meta-analysis. Br J Cancer. 2014;110(7): 1862-70.
  37. 37..
    Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79-87.
  38. 38..
    Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079-92.
  39. 39..
    Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: a global context. Salud Publica Mex. 2016;58(2):104-17.
  40. 40..
    Wong MCS, Goggins WB, Wang HHX, Fung FD, Leung C, Wong SY, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862-74.
  41. 41..
    Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urol. 2019;19(1):19.
  42. 42..
    Winter A, Sirri E, Jansen L, Wawroschek F, Kieschke J, Castro FA, et al. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?. BJU Int. 2017;119(4):550-9.
  43. 43..
    Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167(7):449-55.
  44. 44..
    Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175-81.
  45. 45..
    Michaeli T, Michaeli D. Prostate cancer follow-up costs in Germany from 2000 to 2015. J Cancer Surviv. 2022;16(1):86-94.
  46. 46..
    Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol. 2002;167(1):57-60.
  47. 47..
    Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639-53.
  48. 48..
    Raheem OA, Khandwala YS, Sur RL, Ghani KR, Denstedt JD. Burden of urolithiasis: trends in prevalence, treatments, and costs. Eur Urol Focus. 2017;3(1):18-26.
  49. 49..
    Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)—focus on the UK. BJU Int. 2015;115(4):508-19.
  50. 50..
    Lu PL, Liu YC, Toh HS, Lee YL, Liu YM, Ho CM, et al. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009–2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2012;40(Suppl):S37-43.
  51. 51..
    Li X, Fan H, Zi H, Hu H, Li B, Huang J, et al. Global and regional burden of bacterial antimicrobial resistance in urinary tract infections in 2019. J Clin Med. 2022;11(10):2817.
  52. 52..
    Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031.
  53. 53..
    Jin YH, Wang YP, Xie YL, Tian GH, Zhang XY, Shi NN, et al. Research on the development methodology for clinical practice guidelines for organic integration of traditional Chinese and Western medicine. Mil Med Res. 2023;10(1):45.

Leia o texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website